25. Hunninghake D, Stein E, Dujovne C, et al. The efficacy of inten. sive dietary therapy alone or combined with lovastatin in o u t pat ients with hypercholesterolemia. N Engl J Med. 1993;328: 1213-9. 26, Henkin Y, Garber D, Osterlund L, Darnell B. Saturated fats, cholesterol, and dietary compliance. Arch Intern Med. 1992;152:1167-74. 27. Illingworth D, Stein W, Mitchel Y, et al. Comparative effects of lovas ta t in and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med. 1994; 154:1586-95. 28. Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants , niacin, psyllium and lovastatin) for treating hypercholesterotemia in veterans. Am J Cardiol. 1993;71:759-65. 29. Andrade S, Walker A, Gottlieb L, et al. Discontinuation of antihy .~ perlipidemic drugs. Do rates reported in clinical trials reflect rates in primary care sett ings? N Engl J Med. 1995:332:1125-31. 30. Heudebert G. Ruiswyk JV. Hiatt J , Schectman G, Combination drug therapy for h,c~ercholesterolemia: the trade-off between cost and simplicity. Arch Intern Med. 1993:153:1828-37. 31. The Lipid Research Clinics Program. The Lipid Research Clinics Primary Prevention Trial results, I: reduction in the incidence of coronary heart disease. J,~MA. 1984;251:351-64. 32. Shear C, Franklin F, Stinnett S, et al. Expanded Clinical Evaluation of Lovastatin [EXCEL) s tudy results. Effect of pat ient characteristics on lovastat in-induced changes in p lasma concentrations of lipids and lipoproteins. Circulation. 1992:85:1293-303.